Organ specific cytotoxicity test systems are for clients who are gathering initial information on how a compound may impact organ health. Knowing how test compounds interact with a simple one compartment system is necessary before more complex models can be used.
A single organ is used to identify mechanisms of toxicity, screen a large number of compounds for efficacy or toxicity relative to reference compounds and then use these data to rank order compounds.
Single organ testing is used to identify adverse outcome pathways and targets of toxicity critical to understanding overall chemical hazard and for performing risk assessment.
Many of the in vitro methods used industry wide were pioneered by IONTOX founder Dr. James Mckim 15 years ago. IONTOX continues this trend of innovation by, finding and developing the latest in vitro toxicity testing and putting them to work for your business.
ET 50 (Potency)
Predict the potential of your test compound or xenobiotic to cause ocular irritation using our Eye Irritation Test (EIT).
Historically, ocular irritation was performed on rabbits using the Draize Eye Test.2 However, three-dimensional human corneal tissue equivalents have been developed and validated as replacements for the Draize test. These 3D tissues are nonkeratinized, corneal epithelia grown from normal human keratinocytes and are extremely similar to native human cornea, both metabolically and morphologically. In addition, the apical surface is direct contact with the air (tissue is fed basally) allowing for testing of almost all types materials, such as gels, creams liquids, and powders, regardless of aqueous solubility.
Companies with new compounds seeking to identify and understand potential adverse effects from chemical exposure must understand liver toxicity as a first step.
The liver regulates several important processes necessary for survival and is often the first organ to be exposed to a test agent. Therefore, understanding compound effects on liver is a critical first step.
In addition to standard liver models and screens IONTOX has attained an exclusive license to screen for IDILI Liability in vitro.
Pharmaceutical, tobacco, nutraceutical, cosmetic, and agro-chemical companies often need to identify hazards associated with inhalation of products.
Many chemical agents gain entry to the body via inhalation and therefore assessment of normal lung function is essential for understanding chemical safety.
Pharmaceutical, chemical, and cosmetic companies are responsible for knowing that their products are safe for human use and in the event of misuse that any adverse systemic effects are known.
An important challenge for these industries is the immediate need to reduce or replace animal testing. This means that in vitro alternatives must be found to test new drug candidates, chemical ingredients, or finished products.
In the past, companies could evaluate the safety of new drugs, chemicals, or finished products in animal studies. Although, some animal studies are still done on a routine basis there is real regulatory, consumer, and corporate pressure to reduce, refine, and even replace animal toxicity testing.
Pharmaceutical, nutraceutical, food additive, and chemical companies need to know how their compounds affect the intestinal cell health. Chemicals entering the intestinal tract can affect the intestinal epithelium.
Compounds that enter the body by the oral route, enter the gastrointestinal tract (GIT). The GIT is a complex system that facilitates the digestion and absorption of food derived fats, carbohydrates, and proteins. The primary site of enzymatic breakdown and absorption is the upper portion of the small intestine (duodenum). Chemicals that enter the intestine via ingestion of medicines or food products are absorbed into the portal circulation and carried to the liver. During the absorption process compounds can undergo metabolism by Cytochrome P450 enzymes in the intestinal epithelium. Exogenous compounds can also induce inflammatory responses in the intestine or cause direct toxicity.